OSE Immunotherapeutics And Servier Join Forces In Auto-Immune Field
Executive Summary
French groups OSE Immunotherapeutics and Servier have inked a pact to develop and commercialize the newly formed biotech's interleukin-7 antagonist in ulcerative colitis.